Skip to content

US · JAGX · BIOTECHNOLOGY

Jaguar Health, Inc. (JAGX) intrinsic value and stock valuation

$0.23as of 2026-11-21 · Mkt cap 70.31K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Jaguar Health, Inc. DCF and intrinsic value

InvestorsCraft values JAGX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from JAGX’s statements →

Jaguar Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Francisco, CA 94104 jaguar.health

How the business is doing

Fiscal 2014–2025, USD

Revenue
$11.5M+4.2% 5y CAGRd
20142025
Net income
-$-53.43M
20142025
Free cash flow
$5.77M
20142025
Total equity
-$-18.69M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$11.5M$11.7M$9.76M$12M$4.33M
Operating income-$-45.11M-$-30.83M-$-34.29M-$-34.41M-$-40.71M
Net income-$-53.43M-$-38.49M-$-41.3M-$-47.45M-$-52.59M
EPSd-$-763.29M-$-3.85B———
Operating cash flow$5.8M-$-29.38M-$-33.24M-$-33.1M-$-34.97M
Capital expenditure-$-30K-$-230K$0.00-$-1.68M-$-10K
Free cash flow$5.77M-$-29.61M-$-33.24M-$-34.78M-$-34.98M
Total assets$38.3M$53.4M$50.8M$47.5M$53.3M
Total debt$43.6M$36.5M$37.1M$34.8M$29.4M
Net debt$42.6M$28.5M$30.6M$29.4M$12.3M
Total equity-$-18.69M$6.49M$4.9M-$-1.36M$11.9M
Cash and short-term investments$970K$8M$6.47M$5.47M$17.1M
Income statement
20252024202320222021
Revenue$11.5M$11.7M$9.76M$12M$4.33M
Cost of revenue$3.77M$1.96M$2.04M$2.02M$2.33M
Gross profit$7.74M$9.73M$7.72M$9.94M$2M
Research and development expenses$25M$16.5M$18.6M$17.7M$15.1M
Selling, general and administrative expenses$26M$24M$23.1M$26.7M$26M
Other expenses$1.86M$0.00$370K$0.00$1.63M
Operating expenses$52.8M$40.6M$42M$44.4M$42.7M
Cost and expenses$56.6M$42.5M$44.1M$46.4M$45M
Interest income$0.00$0.00$0.00$0.00$8.42M
Interest expense-$-70K$230K$6.38M$12.7M$8.42M
Depreciation and amortization$2.2M$2.36M$1.16M$2.29M$1.81M
Ebitda-$-51.73M-$-36.66M-$-32.76M-$-33.38M-$-42.37M
Operating income-$-45.11M-$-30.83M-$-34.29M-$-34.41M-$-40.71M
Total other income/expenses, net-$-8.89M-$-8.42M-$-7.61M-$-13.98M-$-11.89M
Income before tax-$-54M-$-39.25M-$-41.9M-$-48.4M-$-52.6M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-53.43M-$-38.49M-$-41.3M-$-47.45M-$-52.59M
Weighted average shares outstanding$70K$10K$0.00$0.00$0.00
Weighted average diluted shares outstanding$70K$10K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$970K$8M$6.47M$5.47M$17.1M
Net receivables$1.7M$1.65M$2.18M$2.47M$2.14M
Inventory$8.6M$10.4M$9.19M$7.02M$4.9M
Total current assets$20.3M$32.2M$28M$22.3M$28.4M
Property, plant and equipment, net$1.46M$1.4M$1.67M$1.7M$1.73M
Goodwill and intangible assets$16M$18.5M$20.1M$22.4M$22.7M
Long-term investments$320K$0.00$0.00$0.00$0.00
Total non-current assets$18M$21.2M$22.8M$25.1M$24.8M
Total assets$38.3M$53.4M$50.8M$47.5M$53.3M
Accounts payable$8.69M$5.29M$4.97M$5.81M$4.93M
Short-term debt$27.6M$12.3M$5.21M$16.4M$3.42M
Deferred revenue$170K$170K$0.00$0.00$0.00
Total current liabilities$40.7M$19.7M$14M$30.3M$15.5M
Long-term debt$16M$24.2M$31.9M$18.5M$25.9M
Deferred revenue, non-current$380K$550K$0.00$0.00$0.00
Total non-current liabilities$16.4M$27.2M$31.9M$18.5M$25.9M
Capital lease obligations$1.08M$980K$1.23M$1.21M$1.16M
Total liabilities$57M$46.9M$45.9M$48.8M$41.4M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-399.92M-$-346.48M-$-308.25M-$-266.95M-$-219.49M
Accumulated other comprehensive income (loss)-$-830K-$-470K-$-650K-$-680K$0.00
Total equity-$-18.69M$6.49M$4.9M-$-1.36M$11.9M
Total investments$320K$0.00$0.00$0.00$0.00
Total debt$43.6M$36.5M$37.1M$34.8M$29.4M
Net debt$42.6M$28.5M$30.6M$29.4M$12.3M
Cash flow statement
20252024202320222021
Net income-$-15.37M-$-39.03M-$-41.87M-$-49.08M-$-52.6M
Depreciation and amortization$0.00$2.36M$2.39M$2.29M$1.81M
Stock-based compensation-$-810K$1.64M$2.11M$3.32M$3.97M
Change in working capital$12.9M-$-3.01M-$-11.1M-$-4.43M$2.27M
Accounts receivable-$-430K$530K$300K-$-170K$2.82M
Inventory$900K-$-1.16M-$-2.17M-$-2.12M-$-2.12M
Accounts payable$3.02M$330K-$-850K$900K$160K
Net cash provided by operating activities$5.8M-$-29.38M-$-33.24M-$-33.1M-$-34.97M
Investments in property, plant and equipment-$-30K-$-20K$0.00-$-80K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$250K
Net cash used for investing activities$150K-$-230K$0.00-$-1.68M-$-10K
Common stock issued$1.86M$31.9M$32.1M$20.5M$33.6M
Common stock repurchased-$-31.07M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-44.33M$31.2M$34.2M$23.2M$43.9M
Net change in cash-$-38.35M$1.53M$1M-$-11.58M$8.96M
Cash at end of period$7.83M$8M$6.47M$5.47M$17.1M
Operating cash flow$5.8M-$-29.38M-$-33.24M-$-33.1M-$-34.97M
Capital expenditure-$-30K-$-230K$0.00-$-1.68M-$-10K
Free cash flow$5.77M-$-29.61M-$-33.24M-$-34.78M-$-34.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Jaguar Health, Inc.

        Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

        CEO
        Lisa A. Conte
        Employees
        47
        Beta
        -0.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Jaguar Health, Inc. (JAGX)?

        InvestorsCraft does not currently publish an intrinsic value for JAGX. How the IC value is calculated.

        Is JAGX undervalued?

        InvestorsCraft does not publish an undervaluation signal for JAGX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.